Dingdong (Cayman) Expands Testing with New GMP Lab in Minnesota
- DDL launched a new 10,600 square foot GMP lab in Eden Prairie, Minnesota, enhancing drug-device testing capabilities.
- The facility specializes in ICH stability testing and performance testing for devices like auto injectors and pre-filled syringes.
- DDL aims to showcase its new GMP capabilities at the INTERPHEX conference in April 2025, engaging industry stakeholders.
DDL Expands Testing Capabilities with New GMP Laboratory in Minnesota
DDL, a leading provider of testing services for the pharmaceutical and biotech industries, launches a new 10,600 square foot Good Manufacturing Practice (GMP) laboratory in Eden Prairie, Minnesota. This facility, which is registered with the FDA, is designed to enhance DDL's capabilities in drug-device combination product testing, responding to the increasing demand for regulatory-compliant testing solutions across various sectors. As the life sciences industry continues to evolve, the new lab positions DDL to play a pivotal role in ensuring that manufacturers can deliver safe and effective products to market efficiently and effectively.
The GMP laboratory will specialize in a range of critical testing services, including ICH stability testing and ISO 11040 and ISO 11608 testing, which focus on the functional and mechanical performance of devices such as auto injectors and pre-filled syringes. John Koch, General Manager, emphasizes that this facility empowers manufacturers to meet the rigorous standards demanded by regulatory bodies, thereby reinforcing DDL's commitment to excellence within the life sciences sector. With over 35 years of industry experience, the firm’s dedication to high-quality testing services is clear, as it aims to support manufacturers through comprehensive testing processes that adhere to stringent compliance regulations.
In addition to the Eden Prairie facility, DDL maintains laboratories in Irvine, California, and Edison, New Jersey, strategically positioning itself to serve clients across the nation. The company plans to showcase its newly established GMP testing capabilities at the upcoming INTERPHEX conference, scheduled for April 1-3, 2025, at the Javits Center in New York. This event will provide an opportunity for DDL to demonstrate its wide array of services and engage with industry stakeholders looking for reliable testing solutions.
DDL's expansion reflects a broader trend within the life sciences industry, where the demand for robust testing services continues to grow. With its strategic investments in new facilities and a focus on regulatory compliance, DDL is well-equipped to navigate the challenges of an ever-evolving market. Interested parties can learn more about DDL’s comprehensive testing services by visiting their website at www.DDLTesting.com or contacting them directly for inquiries.